13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001263508
Total reported value
$20.0B
$20.0B
86 檔
46.4%
At the close of Q4 2025, Baker Bros. Advisors LP disclosed equity holdings valued at approximately $20.0B, spread across 86 reported holdings.
In Q4 2025, Baker Bros. Advisors LP displayed an active expansion posture, initiating 9 new positions and adding to 23 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | INCY | Incyte CORP | Stock-Healthcare | 17.78% | +0.86% | +0.00% | |
| 2 | ONC | Beone Medicines Ltd-adr | Stock-Other | 15.65% | -2.43% | — | |
| 3 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 7.30% | -0.67% | — | |
| 4 | INSM | Insmed Inc | Stock-Healthcare | 6.72% | -2.27% | -1.65% | |
| 5 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 6.71% | -0.04% | — | |
| 6 | CELC | Celcuity Inc | Stock-Other | 4.62% | -1.04% | — | |
| 7 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 4.41% | +5.40% | — | |
| 8 | KYMR | Kymera Therapeutics Inc | Stock-Other | 3.94% | +0.83% | +30.16% | |
| 9 | SMMT | Summit Therapeutics Inc | Stock-Other | 3.73% | -1.57% | +7.91% | |
| 10 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 3.51% | +0.32% | — | |
| 11 | KOD | Kodiak Sciences Inc | Stock-Other | 3.26% | -0.47% | +15.07% | |
| 12 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.94% | -0.30% | +63.38% | |
| 13 | ALKS | Alkermes plc | Stock-Healthcare | 1.64% | +0.60% | +23.74% | |
| 14 | GRAL | Grail Inc | Stock-Healthcare | 1.05% | +0.18% | +27.92% | |
| 15 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.96% | -0.44% | -9.99% | |
| 16 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 0.85% | +0.09% | +30.22% | |
| 17 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.83% | -0.07% | +216.13% | |
| 18 | IMVT | Immunovant Inc | Stock-Other | 0.81% | +0.27% | — | |
| 19 | ✓ | Immatics NV | Stock-Other | 0.74% | -0.14% | — | |
| 20 | IDYA | Ideaya Biosciences Inc | Stock-Other | 0.73% | +0.18% | +10.48% | |
| 21 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.71% | +0.07% | +47.44% | |
| 22 | ABVX | Abivax Sa-adr | Stock-Other | 0.69% | -0.56% | EXIT | |
| 23 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.68% | +0.13% | +0.06% | |
| 24 | REPL | Replimune Group Inc | Stock-Other | 0.63% | +0.12% | — | |
| 25 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.62% | -0.07% | -27.99% | |
| 26 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.58% | -0.01% | -7.94% | |
| 27 | ABCL | Abcellera Biologics Inc | Stock-Other | 0.55% | +0.69% | — | |
| 28 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.52% | +0.16% | +20.00% | |
| 29 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.47% | -0.13% | EXIT | |
| 30 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.45% | -0.06% | — | |
| 31 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.45% | -0.05% | +488.88% | |
| 32 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.40% | +0.12% | -11.60% | |
| 33 | CELC 2.75 08-01-31Bond | Celcuity Inc | Bond | 0.39% | -0.08% | — | |
| 34 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.37% | — | — | |
| 35 | DNLI | Denali Therapeutics Inc | Stock-Other | 0.36% | +0.07% | — | |
| 36 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.36% | — | +13.03% | |
| 37 | TRDA | Entrada Therapeutics Inc | Stock-Other | 0.31% | -0.18% | +4.25% | |
| 38 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.27% | +0.04% | — | |
| 39 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.22% | — | — | |
| 40 | BNTX | Biontech Se-adr | Stock-Other | 0.21% | — | — | |
| 41 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.19% | -0.29% | EXIT | |
| 42 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.19% | +0.01% | — | |
| 43 | PRLD | Prelude Therapeutics Inc | Stock-Other | 0.17% | +0.07% | — | |
| 44 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 0.16% | -0.06% | — | |
| 45 | IRON | Disc Medicine Inc | Stock-Other | 0.16% | — | — | |
| 46 | JBIO | Jade Biosciences Inc | Stock-Other | 0.15% | +0.01% | — | |
| 47 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.13% | +0.04% | — | |
| 48 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 0.13% | — | — | |
| 49 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.12% | — | +129.62% | |
| 50 | ARGX | Argenx Se - Adr | Stock-Healthcare | 0.12% | -0.11% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CELC | Celcuity Inc | +1.8% | — | Unchanged |
| 2 | PRAX | Praxis Precision Medicines I | +1.7% | +63.38% | Add |
| 3 | RVMD | Revolution Medicines Inc | +1.2% | — | Unchanged |
| 4 | KYMR | Kymera Therapeutics Inc | +1.2% | +30.16% | Add |
| 5 | KOD | Kodiak Sciences Inc | +1.2% | +15.07% | Add |
| 6 | IONS | Ionis Pharmaceuticals Inc | +0.6% | +216.13% | Add |
| 7 | ARWR | Arrowhead Pharmaceuticals In | +0.4% | +30.22% | Add |
| 8 | CRNX | Crinetics Pharmaceuticals In | +0.4% | +488.88% | Add |
| 9 | GRAL | Grail Inc | +0.4% | +27.92% | Add |
| 10 | ROIV | Roivant Sciences Ltd. | +0.3% | +47.44% | Add |
| 11 | REPL | Replimune Group Inc | +0.3% | — | Unchanged |
| 12 | GPCR | Structure Therapeutics Inc | +0.3% | -7.94% | Trim |
| 13 | NRIX | Nurix Therapeutics Inc | +0.3% | +20.00% | Add |
| 14 | MDGL | Madrigal Pharmaceuticals Inc | +0.2% | — | Unchanged |
| 15 | IMVT | Immunovant Inc | +0.2% | — | Unchanged |
| 16 | ABVX | Abivax Sa-adr | +0.2% | — | Unchanged |
| 17 | GLUE | Monte Rosa Therapeutics Inc | +0.1% | -11.60% | Trim |
| 18 | TRDA | Entrada Therapeutics Inc | +0.1% | +4.25% | Add |
| 19 | ACAD | Acadia Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 20 | EWTX | Edgewise Therapeutics Inc | +0.1% | -9.99% | Trim |
| 21 | VTYXUSD | Ventyx Biosciences Inc | +0.1% | +129.62% | Add |
| 22 | TECX | Tectonic Therapeutic Inc | +0.1% | +803.40% | Add |
| 23 | IDYA | Ideaya Biosciences Inc | +0.1% | +10.48% | Add |
| 24 | CELC 2.75 08-01-31Bond | Celcuity Inc | +0.1% | — | Unchanged |
| 25 | VRDN | Viridian Therapeutics Inc | +0.1% | +13.03% | Add |
| 26 | CTNM | Contineum Therapeutics Inc-a | +0.1% | +1729.33% | Add |
| 27 | SYRE | Spyre Therapeutics Inc | +0.1% | — | Unchanged |
| 28 | PRLD | Prelude Therapeutics Inc | +0.1% | — | Unchanged |
| 29 | DBVT | Dbv Technologies Sa-spon Adr | +0.1% | — | Unchanged |
| 30 | ALMS | Alumis Inc | 0% | — | Unchanged |
| 31 | TSHA | Taysha Gene Therapies Inc | 0% | — | Unchanged |
| 32 | DSGN | Design Therapeutics Inc | 0% | +30.37% | Add |
| 33 | SION | Sionna Therapeutics Inc | 0% | — | Unchanged |
| 34 | RLAY | Relay Therapeutics Inc | 0% | — | Unchanged |
| 35 | CTMX | Cytomx Therapeutics Inc | 0% | — | Unchanged |
| 36 | XNCR | Xencor Inc | 0% | — | Unchanged |
| 37 | WVE | Wave Life Sciences Ltd. | 0% | — | Unchanged |
| 38 | TARA | Protara Therapeutic Inc | 0% | +80.99% | Add |
| 39 | VTVT | Vtv Therapeutics Inc- Cl A | 0% | — | Unchanged |
| 40 | LBRX | Lb Pharmaceuticals Inc | 0% | — | Unchanged |
| 41 | ✓ | Immatics NV | — | — | Unchanged |
| 42 | CERS | Cerus CORP | — | — | Unchanged |
| 43 | IRON | Disc Medicine Inc | — | — | Unchanged |
| 44 | NGNE | Neurogene Inc | — | — | Unchanged |
| 45 | ELVN | Enliven Therapeutics Inc | — | +136.35% | Add |
| 46 | KALAEUR | Kala Bio Inc | — | +83.14% | Add |
| 47 | VIR | Vir Biotechnology Inc | — | — | Unchanged |
| 48 | TYRA | Tyra Biosciences Inc | — | — | Unchanged |
| 49 | ACRV | Acrivon Therapeutics Inc | — | — | Unchanged |
| 50 | SRZNW | Surrozen Inc-cw25 | — | — | Unchanged |
According to official SEC Form 13F filings, Baker Bros. Advisors LP reported a total U.S. public equity portfolio value of $20.0B across 86 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including INCY, ONC, MDGL) accounted for 46.4% of total reported equity market value during Q4 2025.
Top New Position Initiated
430
市值: $38.4M
Top Position Liquidated / Trimmed
MERUS N V
前期市值: $54.1M
During Q4 2025, Baker Bros. Advisors LP's top holdings by market value included INCY (17.8%)、ONC (15.7%)、MDGL (7.3%). The largest single position, INCY, represented 17.8% of total portfolio value.
In Q4 2025, Baker Bros. Advisors LP made 53 total portfolio adjustments, initiating 9 new buys, adding to 23 positions, trimming 7 holdings, and fully liquidating 14 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.